MAC Clinical Research (MAC) is proud to announce the acquisition of Intelligent Clinical, a clinical research site that specialises in phase II – IV clinical trials, based in the city of Glasgow.
Intelligent Clinical bring with them a wealth of clinical and scientific expertise, adding to MACs rich history and vast experience in conducting clinical studies.
Dr Steve Higham, President of MAC Clinical Research highlighted that “Establishing a clinic in Glasgow provides greater UK coverage for MAC and significantly expands its participant reach. Almost 35 million people across the UK now live within 20 minutes of a MAC research site. The acquisition of Intelligent Clinical will not only broaden MACs geographical footprint, but also strengthen its ability to conduct diverse studies across many therapeutic areas.”
The UK remains one of the best geographic regions for conducting clinical research, and MAC is strongly positioned to offer pharmaceutical and biotech customers the highest quality clinical trials, with many in-house facilities to provide a unique advantage to those who partner with them.
MAC continues this new chapter of growth alongside the recent addition of a new site in Birmingham and remains dedicated to upholding the highest standards of excellence and integrity in clinical research.
Dr Morag McFarlane, CEO of The Niche CRO Group added “We are pleased that Intelligent Clinical has found a good home with MAC Clinical Research. Our focus is now on growing HistologiX, a trusted GLP & GCP compliant CRO for tissue-based analysis, whilst looking for possible acquisitions for the group.
For more information about MACs clinical research sites, extensive range of services and ongoing studies, click here.
About MAC Clinical Research
MAC Clinical Research is a leading global contract research organisation (CRO), owning a network of dedicated research sites dedicated to the recruitment and conduct of clinical trials. MAC conducts research across multiple therapeutic areas including CNS, Men and Women’s Health, Dermatology, and more. MAC has an extensive range of clinical capabilities to accommodate even the most complex trials from Phase I to Phase IV, as well as MHRA-accredited Early Phase and GMP facilities providing in-house services in all areas of clinical research.
For more information, visit www.macplc.com.
About The Niche CRO Group Limited
Niche CRO provides investment and head office function for group companies.
HistologiX helps clients visualise key biomarkers at the cellular and tissue level, working across the drug discovery pipeline from support preclinical research through to clinical trial support. HistologiX provides expertise in histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), In Situ Hybridisation (ISH) & cutting-edge digital image analysis.
For more information, visit www.histologix.com.
